Dynavax Technologies Poised for a Groundbreaking Year: A Vaccine Revolution
Dynavax Technologies reports record-breaking revenues driven by their HEPLISAV-B hepatitis B vaccine, capturing 44% of the U.S. market. The company projects 2025 revenues to soar between $305 million and $325 million, underscoring their dominant market presence. Dynavax aims to revolutionize the shingles
